Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 256 | 46 | 210 |
| Samples | 93 | 26 | 67 |
| Peptides | 71 | 14 | 59 |
Function
CDKN2C · Cyclin dependent kinase inhibitor 2C
The protein encoded by this gene is a member of the INK4 family of cyclin-dependent kinase inhibitors. This protein has been shown to interact with CDK4 or CDK6, and prevent the activation of the CDK kinases, thus function as a cell growth regulator that controls cell cycle G1 progression. Ectopic expression of this gene was shown to suppress the growth of human cells in a manner that appears to correlate with the presence of a wild-type RB1 function. Studies in the knockout mice suggested the roles of this gene in regulating spermatogenesis, as well as in suppressing tumorigenesis. Two alternatively spliced transcript variants of this gene, which encode an identical protein, have been reported. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 71 amino-acid changes on canonical ENST00000371761 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CDKN2C · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CDKN2C – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Glioblastoma | 5/98 5% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 6/612 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Ovarian Carcinoma | 2/109 2% | 3/998 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Bladder Carcinoma | 2/58 3% | 2/956 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| Kidney Carcinoma | 0/85 0% | 6/1862 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Colorectal Carcinoma | 0/143 0% | 9/3239 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 6/2550 0% |
| Gastric Carcinoma | 1/74 1% | 3/1809 0% |
| Melanoma | 0/210 0% | 4/1899 0% |
| Other Solid Cancers | 0/94 0% | 3/1515 0% |
| Hepatocellular Carcinoma | 2/46 4% | 2/2210 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Breast Carcinoma | 4/144 3% | 0/3264 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Neuroblastoma | 1/87 1% | 0/1331 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 1/1390 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 1/1592 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| Head and Neck Carcinoma | 0/85 0% | 1/1574 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 1/2534 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 1/2640 0% |
Mutation Distribution
Where CDKN2C is mutated · all tissues, split by cell line vs tissue
How many mutations in CDKN2C were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 256 mutations in CDKN2C
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|